SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-18-007419
Filing Date
2018-05-18
Accepted
2018-05-18 12:20:38
Documents
59
Period of Report
2018-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm 10-Q 604597
2 ex31-1.htm EX-31.1 13947
3 ex32-1.htm EX-32.1 8259
4 logo_001.jpg GRAPHIC 38214
  Complete submission text file 0001493152-18-007419.txt   3212484

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE FILE endv-20180331.xml EX-101.INS 469010
6 XBRL SCHEMA FILE endv-20180331.xsd EX-101.SCH 39235
7 XBRL CALCULATION FILE endv-20180331_cal.xml EX-101.CAL 45721
8 XBRL DEFINITION FILE endv-20180331_def.xml EX-101.DEF 159762
9 XBRL LABEL FILE endv-20180331_lab.xml EX-101.LAB 291505
10 XBRL PRESENTATION FILE endv-20180331_pre.xml EX-101.PRE 237654
Mailing Address 6320 CANOGA AVENUE 15TH FLOOR WOODLAND HILLS CA 91367
Business Address 6320 CANOGA AVENUE 15TH FLOOR WOODLAND HILLS CA 91367 (800) 489-4774
ENDONOVO THERAPEUTICS, INC. (Filer) CIK: 0001528172 (see all company filings)

IRS No.: 452552528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-55453 | Film No.: 18845729
SIC: 2834 Pharmaceutical Preparations